HBV Mutation Detail Information

> L180M Search Result

Mutation Information

Mutation Site	L180M
Mutation Type	Amino acid level
Gene/Protein/Region Type	RT
Immune Escape	Y
Relevant Drug	entecavir (ETV)

Literature Information

PubMed PMID	32084506
Published Year	2020
Journal	Antiviral research
Title	7-Deaza-7-fluoro modification confers on 4'-cyano-nucleosides potent activity against entecavir/adefovir-resistant HBV variants and favorable safety.
Author	Hayashi S,Higashi-Kuwata N,Das D,Tomaya K,Yamada K,Murakami S,Venzon DJ,Hattori SI,Isogawa M,Sarafianos SG,Mitsuya H,Tanaka Y
Evidence	Southern blot analysis using wild-type HBV (HBVWT)-encoding-plasmid-transfected HepG2 cells revealed that CdFA efficiently suppresses the production of HBVWT (IC50 = 153.7 nM), entecavir (ETV)-resistant HBV carrying L180M/S202G/M204V substitutions (HBVETV(R); IC50 = 373.2 nM), and adefovir dipivoxil (ADV)-resistant HBV carrying A181T/N236T substitutions (HBVADV(R); IC50=192.6 nM), whereas ETV and ADV were less potent against HBVETV(R) and HBVADV(R) (IC50: >1,000 and 4,022.5 nM, respectively).

Contents
Description

Mutation Information Note

Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)

Literature Information Note

Evidence: sentence contains this mutation information in the citation